Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis

Title: Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis

Volume: 6 Issue: 4

Author(s): Jorg H.W. Distler and Oliver Distler

Affiliation:

Keywords: Fibrosis, scleroderma, molecular-targeted therapies, Anti-Fibrotic Approaches, Systemic Sclerosis, 5-hydroxy-trypthamine, pro-fibrotic effects, tight-skin 1 (tsk-1), HISTONE DEACETYLASE INHIBITORS, Hyperacetylation, HDACs, anti-fibrotic effects, transcriptional coactivators, multiple malignancies, neoplastic diseases, leukaemia, procainamide, hydralazine, cardiac arrhythmias, RE-CEPTOR γ AGONISTS, PPARγ agonists, Sonic Hedgehog (Shh)

Abstract: In the last years, several key-pathways for the aberrant activation of fibroblasts in SSc have been identified in pre-clinical studies. This review summarizes recently identified molecular targets for novel anti-fibrotic approaches in systemic sclerosis (SSc) and other fibrotic disorders. We will focus on pathways that can be targeted by drugs that are either already approved for other indications or that are currently evaluated in clinical trials.

Cite this article as:

H.W. Distler Jorg and Distler Oliver, Promising Anti-Fibrotic Approaches for Future Treatment of Systemic Sclerosis, Current Rheumatology Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339710793205666

DOI https://dx.doi.org/10.2174/157339710793205666	Print ISSN 1573-3971
Publisher Name Bentham Science Publisher	Online ISSN 1875-6360